bioAffinity Technologies, Inc. (BIAF)vsIDEXX Laboratories Inc (IDXX)
BIAF
bioAffinity Technologies, Inc.
$1.73
-7.98%
HEALTHCARE · Cap: $7.66M
IDXX
IDEXX Laboratories Inc
$562.16
-0.46%
HEALTHCARE · Cap: $44.24B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 78454% more annual revenue ($4.45B vs $5.66M). IDXX leads profitability with a 24.6% profit margin vs -280.6%. IDXX earns a higher WallStSmart Score of 63/100 (C+).
BIAF
Avoid23
out of 100
Grade: F
IDXX
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BIAF.
Margin of Safety
-53.1%
Fair Value
$423.77
Current Price
$562.16
$138.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 70 in profit
Strong operational efficiency at 31.8%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -433.7% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BIAF
The strongest argument for BIAF centers on Price/Book.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bear Case : BIAF
The primary concerns for BIAF are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.
Key Dynamics to Monitor
BIAF profiles as a turnaround stock while IDXX is a mature play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (234M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 23/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
bioAffinity Technologies, Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
Visit Website →IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?